The crypto market is already in a fear-driven consolidation phase (Fear & Greed 29). Any challenge to the credibility of a sector that has seen tokenized longevity projects (e.g., VitaDAO, GenomicDAO) could accelerate capital rotation away from speculative biotech plays into more established assets like BTC or ETH. It also reinforces the broader market's skepticism toward narrative-driven pumps, which aligns with the current low BTC dominance and altcoin season caution.

Longevity researcher Saul Newman criticizes claims about human lifespan limits as hype, deficient data, and shoddy science.